VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Outcomes of CLL patients following treatment with a covalent BTK and BCL2 inhibitor

Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses outcomes of chronic lymphocytic leukemia (CLL) patients following treatment with a covalent BTK and BCL2 inhibitor. Dr Eyre comments on how the treatment paradigm in CLL is changing with an increase in available agents, and further highlights the importance of focusing on patients who progress following treatment with these two agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Roche: Education Honorarium, Advisory Board Honorarium, Travel to scientific conferences
Gilead: Honorarium; Research support; Travel to scientific conferences
KITE: Education Honorarium, Advisory Board Honorarium,
Janssen: Honorarium
Abbvie: Honorarium; Travel to scientific conferences
AstraZeneca: Honorarium, Research funding, Travel to scientific conferences
Loxo Oncology: Advisory Board Honorarium, Trial steering committee
Beigene: Advisory Board Honorarium, Research funding
Incyte: Advisory Board Honorarium
Secura Bio: Advisory Board Honorarium

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter